Protease Biotherapeutics
Filed in archive Corporate and Industrial News , Genomics, Proteomics and Bioinformatics , Patents and Intellectual Property Rights by ruth on August 08, 2005
According to TPIMS President and director Richard Houghten,
"This agreement represents an example of how the Institute's fundamental technologies are being broadly applied to ground breaking science and drug discovery. The protease selection technology should allow Catalyst to rapidly identify and advance protease biologic leads in a manner analogous to high-throughput small molecule lead discovery and optimization."
The bottomline: To take the fastest route to bringing the results of federally-funded research into some useful form that benefits the public.
Read the press release here.
Permalink: Protease Biotherapeutics
Tags:
protease lead+discovery biotech biotherapeutics corporate protease+biotherapeutics intellectual+prop
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/7964








